Tim Phillips is managing director of ECigIntelligence, the leading source of independent data for the e-cigarette and vaping sector globally, providing unbiased information to numerous leading international companies together with government regulators such as the FDA and the UK government. He is also managing director of a sister publication, CBD-Intel, which is a business intelligence service providing professional, independent market analysis and regulatory tracking for the growing cannabidiol sectors worldwide.
He is a U.K.-qualified attorney, having worked at the European Commission, Herbert Smith, BSkyB, AOL Europe, and as director of public affairs at Betfair as it went through its £1.5bn IPO in 2010. He was also a partner in a New York venture capital-funded startup in the diamond sector. Phillips qualified as a lawyer at the College of Law, London, and holds an MA in Geology from Oxford University.
Matthew R. Holman, Ph.D. is currently Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration (FDA). He was appointed to that position in January 2017. The Office of Science at CTP is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal, they provide the scientific support for regulations and guidance, review tobacco product applications, evaluate the knowledge basis for regulatory decisions, and carry out research to fill the gaps in scientific knowledge related to tobacco product regulation. He received his Ph.D. in Biochemistry from the University of Maryland at College Park in 2000.
Before taking on his current position, Dr. Holman served as Director of the Division of Product Science within CTP’s Office of Science for six years. In this position, he oversaw evaluation of the composition and design of tobacco products. In addition, he was involved in chemical, microbiological, and engineering research on tobacco products, resulting in numerous publications in peer-reviewed scientific journals. During this time, Dr. Holman also served as Technical Project Lead (TPL) in reviewing over a thousand SE Reports. As TPL, he was responsible for the overall scientific review of SE Reports by CTP.
Bio coming soon!
Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His current consulting work focusses on advising manufacturers on regulatory requirements for e-cigarettes as both consumer goods and medicinally-licensed products, in the US, UK and Europe. Prior to starting independent consulting, Ian worked for JUUL Labs as Senior Director of Clinical and Regulatory Affairs EMEA, and previously he was Director of Tobacco Research at Celerion, a provider of clinical research capabilities and regulatory expertise to the tobacco and e-cigarette industries. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical, pre-clinical and behavioural studies to assess the individual and population impact of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation. Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada. Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers which have generated over 3,000 citations.
Mrs. Tedesco-Ciavarra is a Fulbright Scholar with a career spanning the pharmaceutical and regulatory writing industries. Vivienne and her team of writers provide regulatory writing services for study level and summary documents for submissions. Vivienne has worked extensively as the nonclinical lead for regulatory submissions of Regulated Nicotine Products in PMTAs since 2016, and she supports pharmaceutical submissions.
Azim Chowdhury advises domestic and international corporations on regulatory compliance with the U.S. Food and Drug Administration (FDA) and its global counterparts, particularly focusing on vapor, nicotine, tobacco product and cannabis/CBD regulation, as well as food-contact materials.
He counsels tobacco, e-cigarette, e-liquid and CBD manufacturers, distributors, retailers, suppliers, and trade associations on matters relating to regulatory compliance, as well as public policy initiatives. Azim is nationally recognized as an expert on the Family Smoking Prevention and Tobacco Control Act, which amended the Food, Drug and Cosmetic Act to give FDA authority over tobacco products, as well the Agency’s “Deeming Rule” which extended those authorities to previously unregulated products such as electronic nicotine delivery systems (ENDS), e-liquids, cigars, hookah/shisha, and heat-not-burn tobacco products. Azim also advises companies and trade associations on state and global law compliance, including in Canada, the United Kingdom, the EU, and China.